FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Effectiveness of the GRACE risk score according to troponin elevation in patients admitted with non-ST elevation acute coronary syndrome: a post hoc analysis of the UKGRIS parallel group cluster randomised controlled trial. PMID 40571489 · Open Heart · 2025-Jun-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Routine Cerebral Embolic Protection during Transcatheter Aortic-Valve Implantation. PMID 40162661 · N Engl J Med · 2025-Jun-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Development and validation of critical appraisal tool for individual participant data meta-analysis: protocol for a modified e-Delphi study. PMID 40562555 · BMJ Open · 2025-Jun-25 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| [A 30-year review of gastric cancer surgery: China has achieved leapfrog leadership]. PMID 40550663 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Jun-25 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| [Effect of side-to-end anastomosis on postoperative bowel function in rectal cancer surgery: a prospective single-center randomized controlled trial]. PMID 40550657 · Zhonghua Wei Chang Wai Ke Za Zhi · 2025-Jun-25 The study is a randomized Phase III trial in human oncology (rectal cancer) with primary results. However, it is ineligible because the intervention is a surgical technique comparison (not a drug-containing intervention), and the primary endpoint is a quality-of-life/functional outcome (LARS score), not a time-to-event efficacy endpoint as defined by the criteria (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analysis of such). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results. PMID 40553148 · Am J Gastroenterol · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial. PMID 40391436 · Circulation · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Extended Caffeine for Apnea in Moderately Preterm Infants: The MoCHA Randomized Clinical Trial. PMID 40294395 · JAMA · 2025-Jun-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi. PMID 40106688 · Blood Adv · 2025-Jun-24 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial. PMID 40551254 · Breast Cancer Res · 2025-Jun-23 The study meets oncology, human, randomized, time-to-event, drug intervention, and original result criteria. However, the phase of the trial (III/IIIb or II/III) is not explicitly confirmed in the provided metadata or abstract text. The abstract references a trial registration (NCT01042379) but does not specify the phase. Therefore, the 'phase3_or_definitive' criterion cannot be established, and the record is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic endoscopic pylorus dilatation prior to esophagectomy for esophageal cancer to prevent delayed gastric emptying, study protocol for a placebo-controlled randomized trial (PROPPER trial). PMID 40551220 · Trials · 2025-Jun-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. PMID 40550923 · J Cancer Res Clin Oncol · 2025-Jun-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Remote ischaemic preconditioning in cemented hip arthroplasty (the PRINCIPAL study)-randomised controlled trial: study protocol. PMID 40550717 · BMJ Open · 2025-Jun-23 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| The distal nephron biomarkers associate with diabetic kidney disease progression. PMID 40548378 · JCI Insight · 2025-Jun-23 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study. PMID 40473450 · Lancet · 2025-Jun-21 The study is an oncology-related, randomized, phase 3 trial with a drug intervention and original results. However, it is excluded because the primary efficacy endpoint is objective response rate, not a time-to-event endpoint (such as OS, PFS, DFS, EFS, RFS, TTP) or analysis involving Kaplan-Meier curves or hazard ratios, which are required for inclusion in this Kaplan-Meier digitization cohort. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hippocampal avoidance prophylactic cranial irradiation (HA-PCI) for small-cell lung cancer better preserves white matter networks compared to conventional PCI. PMID 39718983 · Neuro Oncol · 2025-Jun-21 This is an original randomized phase 3 trial in oncology, but it evaluates radiation techniques (HA-PCI vs PCI) and reports on neurocognitive and imaging endpoints, not a drug intervention or a time-to-event efficacy endpoint (OS, PFS, etc.). |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [A phase Ⅲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C]. PMID 40660986 · Zhonghua Gan Zang Bing Za Zhi · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| [Phrenic Nerve Cryotherapy for Preventing Prolonged Air Leak During VATS Lobectomy]. PMID 40640090 · Zhongguo Fei Ai Za Zhi · 2025-Jun-20 The study is a randomized trial in oncology (lung cancer) but fails key eligibility criteria: it is not a Phase III/IIIb or Phase II/III drug trial (the intervention is a procedural cryotherapy during surgery, not a drug), and it does not report a time-to-event efficacy endpoint (primary outcome is complication rate, not survival or progression). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. PMID 40367400 · J Clin Oncol · 2025-Jun-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia. PMID 40354592 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Outcomes of Radium-223 and Stereotactic Ablative Radiotherapy Versus Stereotactic Ablative Radiotherapy for Oligometastatic Prostate Cancers: The RAVENS Phase II Randomized Trial. PMID 40334149 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. PMID 40294349 · J Clin Oncol · 2025-Jun-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Long-term (68 weeks) administration of nemolizumab and topical corticosteroids for prurigo nodularis in patients aged ≥ 13 years: efficacy and safety data from a phase II/III study. PMID 40112876 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bimekizumab efficacy and safety through 3 years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period. PMID 39862230 · Br J Dermatol · 2025-Jun-20 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. PMID 40573987 · Vaccines (Basel) · 2025-Jun-19 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A Multicentre, Double-Blind, Randomised, Non-Inferiority Trial of a Novel Single-Injection Intra-Articular HMDA-Cross-Linked Hyaluronate Gel for Knee Osteoarthritis. PMID 40566128 · J Clin Med · 2025-Jun-19 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial. PMID 40537275 · RMD Open · 2025-Jun-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer. PMID 40293180 · N Engl J Med · 2025-Jun-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis. PMID 40202593 · N Engl J Med · 2025-Jun-19 未发现恶性肿瘤人群证据。 |
H
L
B
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Mesenchymal Stem Cells in the Treatment of Diabetic Foot Ulcers: A Meta-Analysis of Randomized Controlled Trials. PMID 40530428 · Int J Low Extrem Wounds · 2025-Jun-18 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial. PMID 40367619 · Eur J Cancer · 2025-Jun-18 The record is a sub-analysis of the APHINITY trial focusing on BMI and weight changes, not the original primary result report of the randomized trial's efficacy. It is a subgroup/post-hoc analysis, which is excluded per the adjudication rules. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| [18F]FET PET-Guided management of pseudoprogression in glioblastoma (FET POPPING): the study protocol for a diagnostic randomized clinical trial. PMID 40528226 · Trials · 2025-Jun-17 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. PMID 40480221 · Cell Rep Med · 2025-Jun-17 The record describes an original, randomized, Phase III oncology trial with drug interventions. However, the primary endpoint is pathological complete response (pCR), a binary categorical outcome, not a time-to-event endpoint (e.g., OS, PFS, DFS). There is no signal of Kaplan-Meier analysis or hazard ratios for a time-to-event endpoint in the abstract or metadata. Therefore, it does not meet the cohort's requirement for a primary/key secondary time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Accelerated Radiotherapy for Complicated Bone Metastases: SHARON Bone Randomized Phase III Trial Shows Non-Inferiority Compared to Standard Palliative Fractionation (NCT03503682). PMID 40563650 · Cancers (Basel) · 2025-Jun-16 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults. PMID 40246546 · Aesthet Surg J · 2025-Jun-16 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. PMID 40526078 · Cancer · 2025-Jun-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Condoliase on Health-related Quality of Life in Participants With Radicular Leg Pain Associated With Lumbar Disk Herniation: Results From a United States Phase 3 Clinical Trial. PMID 40066868 · Spine (Phila Pa 1976) · 2025-Jun-15 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely preterm. PMID 40515786 · Eur J Pediatr · 2025-Jun-14 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluation of machine-learning models to measure individualized treatment effects from randomized clinical trial data with time-to-event outcomes. PMID 40980764 · ArXiv · 2025-Jun-13 The record describes a methodological study evaluating machine learning models using data from randomized trials, but it is not itself a report of an original randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. It lacks explicit Phase III/IIIb or Phase II/III trial evidence and does not report on a specific drug-containing intervention's efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effectiveness of Group and Individual Training in Emotional Freedom Techniques for Patients in Remission from Melanoma: A Randomized Controlled Trial. PMID 40565447 · Healthcare (Basel) · 2025-Jun-13 The study is a randomized controlled trial in human melanoma survivors. It is not a drug intervention trial (evaluates Emotional Freedom Techniques). It does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR); outcomes are psychological/wellbeing measures from questionnaires and distress scores. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Epigallocatechin Gallate in the Treatment and Prevention of Dermatitis: A Systematic Review. PMID 40564177 · Biomedicines · 2025-Jun-13 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Hangeshashinto in delaying grade 2 radiotherapy-induced mucositis development in patients with hypopharyngeal or laryngeal cancer: Preliminary finding of a randomized clinical trial. PMID 40527845 · Medicine (Baltimore) · 2025-Jun-13 The study is an oncology, human, randomized trial with a time-to-event endpoint (Kaplan-Meier) and a drug intervention (herbal medicine). However, it fails the key criterion of being a Phase III/IIIb or Phase II/III trial. The metadata and abstract indicate it is a preliminary, single-center study, with no explicit mention of Phase III. Therefore, it does not meet the eligibility requirement for definitive phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association between rapid and sustained remission and clinician- and patient-reported outcomes in patients with rheumatoid arthritis: post hoc analysis of data from the SELECT-COMPARE study. PMID 40514717 · Arthritis Res Ther · 2025-Jun-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Return to care of children and adolescents living with HIV who missed their clinic visits or were lost to follow-up: a continuous quality improvement study in Uganda. PMID 40514054 · BMJ Open Qual · 2025-Jun-13 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer. PMID 40358364 · Clin Cancer Res · 2025-Jun-13 The study is a randomized Phase II window-of-opportunity study evaluating a biomarker (PARP inhibition) as the primary objective, not a Phase III/IIIb or Phase II/III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. PMID 40227186 · Clin Cancer Res · 2025-Jun-13 The study is an oncology randomized trial with drug intervention and reports OS as a co-primary endpoint, but the abstract does not present any OS results (e.g., survival curves, median, HR) – it only reports organ preservation rates. Furthermore, the trial phase is not confirmed as Phase III or definitive; it appears to be a smaller randomized study possibly Phase II. Therefore, it lacks the explicit Phase III/IIIb or Phase II/III designation and the required time-to-event efficacy results for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial. PMID 40192715 · Clin Cancer Res · 2025-Jun-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. PMID 39326009 · Inflamm Bowel Dis · 2025-Jun-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| [Effect of electroacupuncture on intestinal function after gastric cancer surgery]. PMID 40518778 · Zhongguo Zhen Jiu · 2025-Jun-12 The study is a randomized trial in oncology (gastric cancer surgery) but does not meet key eligibility criteria: 1) The intervention is electroacupuncture combined with enhanced recovery after surgery (ERAS), not a drug-containing intervention. 2) The primary endpoints are functional recovery metrics (intestinal motility, tolerance to oral intake) and inflammatory markers, not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or any analysis with Kaplan-Meier curves or hazard ratios. 3) The trial phase is not specified, but based on the context (post-surgical adjuvant care), it is unlikely to be a Phase III/IIIb or Phase II/III trial of a drug. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous versus intravenous route switch from oral to parenteral morphine in patients with cancer: randomised controlled trial. PMID 40506094 · BMJ Support Palliat Care · 2025-Jun-12 The study is a randomized trial in cancer patients, but it does not meet key eligibility criteria: (1) The intervention compares subcutaneous vs. intravenous administration routes for morphine, not a drug vs. control; (2) The time-to-event endpoints (time to stable infusion rate, time to pain relief) are not standard oncology efficacy endpoints like OS, PFS, etc.; (3) The trial phase is not specified, and it is not clearly a Phase III/IIIb or Phase II/III trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |